Study S001651

A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2)

ClinicalTrials.gov record

Registration

Registration: NCT06192108
Acronym: ACHIEVE-2
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 962
Start: 2024-01-10
Primary completion: 2025-09-26
Lead sponsor: Eli Lilly and Company
Conditions: Type 2 Diabetes
Interventions: DRUG:Orforglipron; DRUG:Dapagliflozin
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:J2A-MC-GZGV; OTHER:2023-507206-13-00; OTHER:U1111-1296-1507; NIH:2023

Registered primary outcomes

Change from Baseline in Hemoglobin A1c: (HbA1c) [Baseline, Week 40]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0007653	Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial. Welch M, Lancet (London, England)	2026	Randomized trial	PMID 42259339 DOI	cites ClinicalTrials.gov:NCT06192108; registry reference DERIVED:42259339
R0054588	1254-OR: Orforglipron vs. Dapagliflozin in Type 2 Diabetes Inadequately Controlled with Metformin MICHELLE D. WELCH, Diabetes	2026	Randomized trial	DOI	cites ClinicalTrials.gov:NCT06192108